ATE204481T1 - Medizinische zusammensetzung zur verwendung für die transfektion und in vivoexpression von exogenen - Google Patents

Medizinische zusammensetzung zur verwendung für die transfektion und in vivoexpression von exogenen

Info

Publication number
ATE204481T1
ATE204481T1 AT96903080T AT96903080T ATE204481T1 AT E204481 T1 ATE204481 T1 AT E204481T1 AT 96903080 T AT96903080 T AT 96903080T AT 96903080 T AT96903080 T AT 96903080T AT E204481 T1 ATE204481 T1 AT E204481T1
Authority
AT
Austria
Prior art keywords
exogenes
vivoexpression
transfection
medical composition
vivo
Prior art date
Application number
AT96903080T
Other languages
English (en)
Inventor
Jean-Francois Bach
Lucienne Chatenoud
Hedi Haddada
Martin Lee
Michel Perricaudet
Michelle Webb
Original Assignee
Aventis Pharma Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Inst Nat Sante Rech Med filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE204481T1 publication Critical patent/ATE204481T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96903080T 1995-02-14 1996-02-12 Medizinische zusammensetzung zur verwendung für die transfektion und in vivoexpression von exogenen ATE204481T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9501662A FR2730411B1 (fr) 1995-02-14 1995-02-14 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
PCT/FR1996/000218 WO1996025177A1 (fr) 1995-02-14 1996-02-12 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes

Publications (1)

Publication Number Publication Date
ATE204481T1 true ATE204481T1 (de) 2001-09-15

Family

ID=9476106

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96903080T ATE204481T1 (de) 1995-02-14 1996-02-12 Medizinische zusammensetzung zur verwendung für die transfektion und in vivoexpression von exogenen

Country Status (23)

Country Link
US (2) US20030004091A1 (de)
EP (1) EP0809516B1 (de)
JP (1) JPH11500430A (de)
KR (1) KR100402540B1 (de)
AT (1) ATE204481T1 (de)
AU (1) AU717218B2 (de)
BR (1) BR9607310A (de)
CA (1) CA2211039C (de)
CZ (1) CZ258197A3 (de)
DE (1) DE69614668T2 (de)
DK (1) DK0809516T3 (de)
ES (1) ES2163612T3 (de)
FI (1) FI119176B (de)
FR (1) FR2730411B1 (de)
GR (1) GR3036438T3 (de)
HU (1) HU222991B1 (de)
IL (1) IL117116A0 (de)
MX (1) MX9706017A (de)
NO (1) NO320072B1 (de)
PT (1) PT809516E (de)
SK (1) SK282235B6 (de)
WO (1) WO1996025177A1 (de)
ZA (1) ZA961161B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
EP0942747A1 (de) * 1996-08-26 1999-09-22 Chiron Corporation Impfungstherapie nach einer hiv-infektion
AU1288099A (en) 1997-10-30 1999-05-24 Cornell Research Foundation Inc. A method of inhibiting an immune response to a recombinant vector
EP1980617A1 (de) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Verbesserte Expression von HIV-Polypeptiden und Herstellung virusähnlicher Partikel
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU5470900A (en) * 1999-06-08 2000-12-28 Children's Hospital Of Philadelphia, The Methods for preventing formation of inhibitory antibodies in the setting of genetherapy
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
MXPA02010993A (es) * 2000-05-12 2003-03-10 Genzyme Corp Reguladores de transmision de la tnf-alfa.
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
US20030211075A1 (en) * 2001-09-27 2003-11-13 Thorpe Philip E. Combined compositions for tumor vasculature coagulation and treatment
AU2003291134A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Use of diamide derivatives for inhibiting chronic tissue transplant rejection
PT1562571E (pt) * 2002-11-21 2011-11-25 Genzyme Corp Combinação de derivados de diamina e agentes imunossupressores para a indução da tolerância imunológica
JP2007520566A (ja) * 2004-02-04 2007-07-26 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5962694A (en) * 1992-12-31 1994-08-15 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
AU5965294A (en) * 1993-01-08 1994-08-15 Exemplar Corporation An (in vitro)/(in vivo) method for identifying anti-neoplastic drugs
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus

Also Published As

Publication number Publication date
CA2211039A1 (fr) 1996-08-22
FI973323A0 (fi) 1997-08-13
US20040265276A1 (en) 2004-12-30
CZ258197A3 (en) 1997-11-12
SK110897A3 (en) 1998-01-14
ZA961161B (en) 1996-08-07
KR19980702199A (ko) 1998-07-15
BR9607310A (pt) 1997-11-25
ES2163612T3 (es) 2002-02-01
MX9706017A (es) 1997-11-29
NO973724L (no) 1997-08-13
FR2730411B1 (fr) 1997-03-28
EP0809516B1 (de) 2001-08-22
FI119176B (fi) 2008-08-29
DE69614668T2 (de) 2002-06-27
KR100402540B1 (ko) 2004-05-07
US20030004091A1 (en) 2003-01-02
WO1996025177A1 (fr) 1996-08-22
NO320072B1 (no) 2005-10-17
SK282235B6 (sk) 2001-12-03
FI973323L (fi) 1997-08-13
DK0809516T3 (da) 2001-12-17
CA2211039C (fr) 2011-12-06
HUP9800635A2 (hu) 1998-07-28
IL117116A0 (en) 1996-06-18
AU717218B2 (en) 2000-03-23
FR2730411A1 (fr) 1996-08-14
HU222991B1 (hu) 2004-01-28
HUP9800635A3 (en) 2000-12-28
NO973724D0 (no) 1997-08-13
AU4723896A (en) 1996-09-04
JPH11500430A (ja) 1999-01-12
PT809516E (pt) 2002-02-28
DE69614668D1 (de) 2001-09-27
EP0809516A1 (de) 1997-12-03
GR3036438T3 (en) 2001-11-30

Similar Documents

Publication Publication Date Title
DE69614668D1 (de) Medizinische zusammensetzung zur verwendung für die transfektion und in vivoexpression von exogenen
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
DE69637156D1 (de) Dna-molekül, herstellung und verwendung in der gentherapie
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
EP0846262A4 (de) Abbildung von spektroskopie von gewebe und anderen stark streuenden medien, basierend auf fluoreszenz lebensdauer
DE69819167D1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
ATE323180T1 (de) Katalytische nukleinsäure und deren medizinische verwendung
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
CY1109367T1 (el) Συνθεσεις και μεθοδοι για ενισχυση της παροχης θεραπευτικων παραγοντων σε κυτταρα
AP9901654A0 (en) Gene sequencer and methods.
IL181695A0 (en) Methods for cultivating cells and propagating viruses
ATE391175T1 (de) Multidrug resistenz gen
MX9801264A (es) Control de la expresion del gen de cd44 para uso terapeutico.
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
ATE373083T1 (de) Methode und zusammensetzungen zur identifizierung von morphogen-analogen
EP0870036A4 (de) Synthetische säugetier alpha-n-aectylglukosaminidase und dafür kodierende genetische sequenzen
EP0985045B1 (de) Modulatoren der expression von morphogenen und deren identifizierungsverfahren
AU7402600A (en) New sequence variants of the human beta1-adrenoreceptor genes and use thereof
DE60024442D1 (de) Verwendung von viralen vektoren und geladenen molekülen für die gentherapie
MX9706725A (es) Mezclas enzimaticas definidas, novedosas para obtener celulas y para tratamientos de heridas.
NZ333515A (en) Polynucleotide encoding a human chemokine beta-15 use in treatment of thymus related diseases
ATE57835T1 (de) Biologisch wirksame substanz mit hormonellen eigenschaften, verfahren zu ihrer herstellung und verwendung von histonen fuer medizinische zwecke.
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.